Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: A novel series of potent dual PDE3/PDE4 inhibitory agents

Journal of Medicinal Chemistry

Volumn 46, Issue 10, 2003, Pages 2008-2016

  Van der Mey, Margaretha ^a,b   Bommelé, Kirsten M ^b   Boss, Hildegard ^c   Hatzelmann, Armin ^c   Van Slingerland, Mike ^b   Sterk, Geert J ^b   Timmerman, Hendrik ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b Byk Nederland   (Netherlands)

^c ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2H PYRIDAZIN 3 ONE; 4A,5,8,8A TETRAHYDRO 2H PHTHALAZIN 1 ONE; 5 METHYL 4,5 DIHYDROPYRIDAZINONE DERIVATIVE; ARACHIDONIC ACID; BENZIMIDAZOLE DERIVATIVE; CIS 4 (3 CHLORO 4 METHOXYPHENYL) 2 [4 [4 (4 METHYL 6 OXO 1,4,5,6 TETRAHYDROPYRIDAZIN 3 YL)PHENOXY]BUTYL] 4A,5,8,8A TETRAHYDRO 2H PHTHALAZIN 1 ONE; CIS 4 (3,4 DIETHOXYPHENYL) 2 [4 [4 (4 METHYL 6 OXO 1,4,5,6 TETRAHYDROPYRIDAZIN 3 YL)PHENOXY]BUTYL] 4A,5,8,8A TETRAHYDRO 2H PHTHALAZIN 1 ONE; ISOENZYME; LY197055; LY264233; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHTHALAZINE DERIVATIVE; PYRIDAZINONE DERIVATIVE; TETRAHYDROBENZIMIDAZOLE DERIVATIVE; TETRAHYDROPHTHALAZINONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG CONFORMATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; EAR EDEMA; EDEMA; ENZYME INHIBITION; HYBRID; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; EDEMA; ENZYME INHIBITORS; MICE; PHTHALAZINES; PYRIDAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037740001     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030776l     Document Type: Article

References (34)

1. Cortijo, J.; Bou, J.; Beleta, J.; Cardelus, I.; Llenas, J.; Morcillo, E.; Gristwood, R. W. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br. J. Pharmacol. 1993, 108, 562-568.
2. Rabe, K. F.; Tenor, H.; Dent, G.; Schudt, C.; Liebig, S.; Magnussen, H. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am. J. Physiol. 1993, 264, L458-L464.
3. De Boer, J.; Philpott, A. J.; Van Amsterdam, R. G.; Shahid, M.; Zaagsma, J.; Nicholson, C. D. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. 1992, 106, 1028-1034.
4. Torphy, T. J.; Undem, B. J.; Cieslinski, L. B.; Luttmann, M. A.; Reeves, M. L.; Hay, D. W. P. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J. Pharmacol. Exp. Ther. 1993, 265, 1213-1223.
5. Giembycz, M. A.; Dent, G. Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin. Exp. Allergy 1992, 22, 337-344.
6. Torphy, T. J.; Undem, B. J. Phosphodiesterase inhibitors: new opportunities for treatment of asthma. Thorax 1991, 46, 512-523.
7. Dent, G.; Giembycz, M. A. Interaction of PDE4 inhibitors with enzymes and cell functions. In Phosphodiesterase Inhibitors; Schudt, C., Dent, G., Rabe, K. F., Eds.; Academic Press: San Diego, 1997.
8. Teixeira, M. M.; Gristwood, R. W.; Cooper, N.; Hellewell, P. G. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci. 1997, 18, 164-171.
9. Bristol, J. A.; Sircar, I.; Moos, W. H.; Evans, D. B.; Weishaar, R. E. Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)-phenyl]-3-(2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. J. Med. Chem. 1984, 27, 1099-1101.
10. Kauffman, R. F.; Crowe, V. G.; Utterback, B. G.; Robertson, D. W. LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol. Pharmacol. 1986, 30, 609-616.
11. Robertson, D. W.; Krushinski, J. H.; Pollock, G. D.; Wilson, H.; Kauffman, R. F.; Hayes, J. S. Dihydropyridazinone cardiotonics: synthesis and inotropic activity of 5′-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)spiro[cycloalkane-1, 3′-[3H]indol] -2′(1′H)-ones. J. Med. Chem. 1987, 30, 824-829.
12. Sircar, I.; Duell, B. L.; Bobowski, G.; Bristol, J. A.; Evans, D. B. Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents. J. Med. Chem. 1985, 28, 1405-1413.
13. Weishaar, R. E.; Cain, M. H.; Bristol, J. A. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J. Med. Chem. 1985, 28, 537-545.
14. Robertson, D. W.; Boyd, D. B. Structural requirements for potent and selective inhibition of low-Km, cyclic-AMP-specific phosphodiesterases. In Advances in Second Messenger and Phosphoprotein Research; Strada, S. J. a. H. H., Ed.; Raven Press: New York, 1992; Vol. 25, pp 321-340.
15. Weishaar, R. E.; Bristol, J. A. Selective inhibitors of phosphodiesterases. Compr. Med. Chem. 1990, 2, 501-514.
16. Davis, A.; Warrington, B. H.; Vinter, J. G. Strategic Approaches to Drug Design. II. Modeling Studies on Phosphodiesterase Substrates and Inhibition. J. Comput.-Aided Mol. Des. 1987, 1, 97-120.
17. Erhardt, P. W.; Hagedorn, A. A. d.; Sabio, M. Cardiotonic agents. 3. A topographical model of the cardiac cAMP phosphodiesterase receptor. Mol. Pharmacol. 1987, 33, 1-13.
18. Erhardt, P. W.; Chou, Y. L. A topographical model for the c-AMP phosphodiesterase III active site. Life Sci. 1991, 49, 553-568.
19. Moos, W. H.; Humblet, C. C.; Sircar, I.; Rithner, C.; Weishaar, R. E.; Bristol, J. A.; McPhail, A. T. Cardiotonic agents. 8. Selective inhibitors of adenosine 3′,5′-cyclic phosphate phosphodiesterase. Elaboration of a five-point model for positive inotropic activity. J. Med. Chem. 1987, 30, 1963-1972.
20. Van der Mey, M.; Boss, H.; Couwenberg, D.; Hatzelmann, A.; Sterk, G. J.; Goubitz, K.; Schenk, H.; Timmerman, H. Novel Selective PDE4 Inhibitors. 4. Resolution, Absolute Configuration, and PDE4 Inhibitory Activity of cis-Tetra and cis-Hexahydrophthalazinones. J. Med. Chem. 2002, 45, 2526-2533.
21. Van der Mey, M.; Van der Laan, I. J.; Timmerman, H.; Hatzelmann, A.; Boss, H.; Häfner, D.; Beume, R.; Kley, H. P.; Sterk, G. J. Preparation of arylphthalazinones as inhibitors of cyclic nucleotide phosphodiesterase. Patent WO 9831674, 1998.
22. Hatzelmann, A.; Boss, H.; Häfner, D.; Beume, R.; Kley, H. P.; Van der Mey, M.; Van der Laan, I. J.; Timmerman, H.; Sterk, G. J. Preparation of phthalazinones as phosphodiesterase IV inhibitors. Patent WO 9931071, 1999.
23. Thibaut, U.; Hatzelmann, A.; Boss, H.; Häfner, D.; Beume, R.; Kley, H. P.; Timmerman, H.; Van der Laan, I. J.; Ulrich, W. R.; Sterk, G. J.; Van der Mey, M. Preparation of phthalazinyldihydrobenzofurans as cyclic nucleotide phosphodiesterase inhibitors. Patent WO 9931090, 1999.
24. Van der Mey, M.; Boss, H.; Hatzelmann, A.; Van der Laan, I. J.; Sterk, G. J.; Timmerman, H. Novel Selective PDE4 Inhibitors. 3. In Vivo Anti-Inflammatory Activity of a New Series of N-Substituted cis-Tetra- and cis-Hexahydrophthalazinones. J. Med. Chem. 2002, 45, 2520-2525.
25. Van der Mey, M.; Hatzelmann, A.; Van Klink, G. P. M.; Van der Laan, I. J.; Sterk, G. J.; Thibaut, U.; Ulrich, W. R.; Timmerman, H. Novel Selective PDE4 Inhibitors. 2. Synthesis and Structure-Activity Relationships of 4-Aryl-Substituted cis-Tetra- and cis-Hexahydrophthalazinones. J. Med. Chem. 2001, 44, 2523-2535.
26. Van der Mey, M.; Hatzelmann, A.; Van der Laan, I. J.; Sterk, G. J.; Thibaut, U.; Timmerman, H. Novel Selective PDE4 Inhibitors. 1. Synthesis, Structure-Activity Relationships, and Molecular Modeling of 4-(3,4-Dimethoxyphenyl)-2H-phthalazin-1-ones and Analogues. J. Med. Chem. 2001, 44, 2511-2522.
27. Hatzelmann, A.; Boss, H.; Häfner, D.; Beume, R.; Kley, H. P.; Van der Laan, I. J.; Timmerman, H.; Sterk, G. J.; Van der Mey, M. Preparation of arylphthalazinones as phosphodiesterase III/IV inhibitors. Patent WO 9947505, 1999.
28. Sterk, G. J.; Van der Mey, M. Phthalazinone PDE III/IV inhibitors. U.S. Patent 6,255,303, 2001.
29. Palfreyman, M. N.; Souness, J. E. 1. Phosphodiesterase type IV inhibitors. In Progress in Medicinal Chemistry; Ellis, G. P., Luscombe, D. K., Eds.; Elsevier Science B. V.: Amsterdam, The Netherlands, 1996; Vol. 33, pp 1-52.
30. Burpitt, B. E.; Crawford, L. P.; Davies, B. J.; Mistry, J.; Mitchell, M. B.; Pancholi, K. D.; Coates, W. J. 6-(Substituted phenyl)-5-methyl-4,5-dihydro-pyridazin-3(2H)-ones of medicinal interest. The synthesis of SK&F 94836 and SK&F 95654. J. Heterocycl. Chem. 1988, 25, 1689-1695.
31. Mertens, A.; Friebe, W. G.; Müller-Beckmann, B.; Kampe, W.; Kling, L.; von der Saal, W. Nonsteroidal cardiotonics. 3. New 4,5-dihydro-6-(1H-indol-5-yl)pyridazin-3(2H)-ones and related compounds with positive inotropic activities. J. Med. Chem. 1990, 33, 2870-2875.
32. Coates, W. J.; McKillop, A. One-pot preparation of 6-substituted 3(2H)-pyridazinones from ketones. Synthesis 1993, 334-342.
33. Leonard, N. J.; Boyd, S. N. Cinnolines. I. Synthesis of aminoacetophenones and aminopropiophenones. J. Org. Chem. 1946, 11, 405-418.
34. Schudt, C.; Winder, S.; Muller, B.; Ukena, D. Zardaverine as a selective inhibitor of phosphodiesterase isoenzymes. Biochem. Pharmacol. 1991, 42, 153-162.